REJECTION OF SLEEP DRUG CAUSES SHARES OF DOV TO NOSE DIVE

Shares of three pharmaceutical companies declined after indiplon, a sleeping medication, failed to win federal approval Tuesday. Shares of Neurocrine Biosciences Inc., which submitted the application, declined 56 percent to close at $23.86, while Pfizer, Neurocrine's marketing and development partner, saw its stock drop 2 cents to close at $24.87.
North Jersey Media Group